Media Coverage

Our commercial intelligence and analysis are used by the Financial Times, the Wall Street Journal, Forbes, Nature, and Reuters, among others. Take a look at the latest Evaluate and Vantage coverage.

If you have questions about Evaluate or require data and expert insights to help support your editorial content, please see our Media Contacts.

Latest Media Coverage

Nature Reviews Drug Discovery

The fragmentation of biopharmaceutical innovation

In the pharmaceutical industry, there are typically 50–120 consolidative deals each year through which two companies become a single entity. So, it could be reasonable to…

Nature Reviews Drug Discovery

Top drugs and companies by sales in 2018

As AbbVie’s Humira (adalimumab) tops the biggest-selling drug list again in 2018, it is hard to see where any challenger might come from to snatch the autoimmune disorder…

Journal of Clinical Pathways

Pathways for Paying for Rare Disease Treatments

According to a 2018 EvaluatePharma Orphan Drug Report, sales of orphan drugs are set to climb by 11% a year through 2024, eventually reaching $262 billion.

Browse the archive

R&D Magazine

The Marriage of Big Pharma and Biotech

Moreover, biotechnology drugs are contributing to sales at a large scale. For EvaluatePharma, these products will represent 31 percent of the market in 2024 in comparison…

Nature Reviews Drug Discovery

The fragmentation of biopharmaceutical innovation

In the pharmaceutical industry, there are typically 50–120 consolidative deals each year through which two companies become a single entity. So, it could be reasonable to…

Nature Reviews Drug Discovery

Top drugs and companies by sales in 2018

As AbbVie’s Humira (adalimumab) tops the biggest-selling drug list again in 2018, it is hard to see where any challenger might come from to snatch the autoimmune disorder…

Vantage logo
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.